文献速递银屑病与炎症性皮肤病

生物制剂使用对银屑病关节炎发生的影响:基于人群的研究

Effect of biologic use on the development of psoriatic arthritis: A population-based study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-11-06

该回顾性队列研究利用美国Optum数据库(2007-2024年),纳入26,470例曾接受光疗的中重度银屑病患者,比较后续换用生物制剂者与继续光疗者新发银屑病关节炎的风险。中位随访期间,生物制剂组PsA发生率低于光疗组,多因素校正后HR为0.66(95%CI 0.53-0.83,p<0.05)。提示生物制剂可能降低或延缓银屑病关节炎的发生。

要点

  • 中重度银屑病患者换用生物制剂后PsA发生率低于继续光疗者。
  • 多因素校正后生物制剂与PsA风险降低相关(HR 0.66,95%CI 0.53-0.83)。
  • 生物制剂可能延缓或预防银屑病关节炎,支持早期积极治疗。

核心结论

  • 在中重度银屑病患者中,启动生物制剂治疗者银屑病关节炎发生率低于继续光疗者,提示生物制剂可能延缓或预防PsA。

研究设计与样本

  • 回顾性队列研究,使用Optum去标识化Clinformatics Data Mart数据库(2007年1月1日至2024年2月29日)。
  • 通过光疗使用识别中重度银屑病患者,排除光疗前已诊断PsA或使用过生物制剂者,并排除生物制剂启动后1年内发生的PsA。
  • 36,508例接受光疗的患者中26,470例符合标准,其中2,611例换用生物制剂,23,859例未换用。

主要发现

  • 总体PsA发生率为7.85/1000人年;继续光疗组为8.06/1000人年,生物制剂组为6.75/1000人年。
  • 多因素校正人口学、合并症、保险类型和口服系统治疗后,生物制剂使用与PsA发生风险降低相关(校正HR 0.66;95%CI 0.53-0.83;p<0.05)。

关键数值与推荐

  • 生物制剂组相比光疗组发生PsA的校正HR为0.66(95%CI 0.53-0.83;p<0.05)。
  • 总体PsA发生率为7.85/1000人年,光疗组8.06/1000人年,生物制剂组6.75/1000人年。

临床怎么用

  • 对中重度银屑病患者,早期使用生物制剂可能不仅改善皮损,还有助于降低未来关节病变风险。
  • 临床决策时可考虑将预防或延缓PsA作为中重度银屑病系统治疗的目标之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic inflammatory skin disorder that often precedes psoriatic arthritis. Conflicting evidence exists regarding whether biologic therapies for psoriasis can prevent or delay psoriatic arthritis onset. OBJECTIVES: To determine whether biologic therapy for psoriasis is associated with a reduced incidence of psoriatic arthritis. METHODS: A retrospective cohort study was performed utilizing Optum's de-identified Clinformatics® Data Mart Database, from January 1, 2007, to February 29, 2024. Patients with moderate-to-severe psoriasis were identified by phototherapy use. Among these, some continued on phototherapy, and others switched to a biologic. Individuals with a psoriatic arthritis diagnosis or history of biologic therapy prior to phototherapy initiation were excluded. Cases of psoriatic arthritis developing within 1 year after biologic initiation were also excluded to minimize protopathic bias. Outcomes included the incidence of psoriatic arthritis, measured as incident cases per 1000 person-years. Hazard ratios (HRs) for psoriatic arthritis development were calculated using a multivariable Cox proportional hazards model. RESULTS: Of 36,508 patients who received phototherapy for psoriasis, 26,470 met eligibility criteria. Among these, 2611 patients switched to biologics, while 23,859 patients did not. The overall PsA incidence rate was 7.85 per 1000 person-years. Patients continuing phototherapy alone had an incidence rate of 8.06 per 1000 person-years, compared with 6.75 in the biologic cohort. After multivariable adjustment for demographics, comorbidities, insurance type and oral systemic therapy, biologic use was associated with a lower likelihood of psoriatic arthritis development compared with phototherapy (adjusted HR, 0.66; 95% CI, 0.53-0.83; p < 0.05). CONCLUSIONS: In this study of moderate-to-severe psoriasis patients, those who initiated biologic therapy demonstrated a lower incidence of psoriatic arthritis than those continuing on phototherapy alone. This suggests that biologic treatments may delay or prevent psoriatic arthritis in psoriasis patients. Psoriasis is a chronic inflammatory skin disease that affects about 3% of people in the United States and over 60 million people worldwide. It causes red, scaly patches on the skin and can significantly affect quality of life. Up to one in three people with psoriasis may later develop psoriatic arthritis, a painful joint condition that can lead to lasting disability. Preventing or delaying psoriatic arthritis (PsA) is therefore an important goal in psoriasis care. Using a large nationwide U.S. health insurance database, we identified 26,542 adults with moderate‐to‐severe psoriasis who initially received phototherapy but with no prior diagnosis of PsA or biologic therapy. We then compared those who later began biologic therapy with those who continued phototherapy only. Over time, patients treated with biologic therapy were less likely to develop psoriatic arthritis than those who remained on phototherapy. This association remained even after accounting for age, sex, and other health factors such as diabetes, hypertension, and alcohol and tobacco use. These findings suggest that early use of biologic therapies in patients with moderate‐to‐severe psoriasis may help reduce the risk of future joint disease. Treating psoriasis effectively may not only improve skin symptoms but also help prevent or delay the onset of psoriatic arthritis, underscoring the importance of timely and targeted treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Miao KL, Huang MY, Guo L, et al. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur Acad Dermatol Venereol. 2025. PMID: 41195984. doi:10.1111/jdv.70167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。